-
Maxim Group Upgrades Cellectar Biosciences (CLRB) to Buy
-
Cellectar Biosciences signs supply deal with Ionetix for radioisotopes
-
Cellectar Biosciences (CLRB) Misses Q3 EPS by 141c
-
Cellectar receives rare pediatric disease designation for brain cancer drug
-
Cellectar Biosciences presents pancreatic cancer drug data at AACR conference
-
Cellectar Biosciences raises $5.8 million through warrant exercise
-
Cellectar gets EMA eligibility for conditional approval of cancer drug
-
Cellectar Biosciences (CLRB) Misses Q2 EPS by 326c
-
Cellectar Biosciences (CLRB) Announces Pricing of $6 Million Underwritten Public Offering
-
Cellectar Biosciences (CLRB) and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
-
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse Stock Split
-
Cellectar Biosciences (CLRB) Provides Update on CLOVER-2 Phase 1 Trial
-
Cellectar Biosciences (CLRB) Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
-
Cellectar Biosciences (CLRB) stock soars on FDA breakthrough designation
-
Cellectar Biosciences (CLRB) Granted FDA Breakthrough Therapy Designation for Iopofosine I 131
-
Cellectar Biosciences (CLRB) Tops Q1 EPS by 30c
-
Cellectar Biosciences (CLRB) to Explore Strategic Alternatives
-
Oppenheimer Reiterates Perform Rating on Cellectar Biosciences (CLRB)
-
Cellectar Biosciences (CLRB) Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
-
Cellectar Biosciences (CLRB) Halted, News Pending
-
Cellectar Biosciences (CLRB) PT Lowered to $12 at Oppenheimer
-
Cellectar Biosciences (CLRB) Misses Q3 EPS by 7c
-
Cellectar Biosciences (CLRB) and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
-
Oppenheimer Reiterates Outperform Rating on Cellectar Biosciences (CLRB)
-
Cellectar Biosciences (CLRB) PT Raised to $14 at Oppenheimer
-
Cellectar Biosciences (CLRB) Reports I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Study

